Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactobacillus Brevis CD2 for Traumatic Oral Lesions in Orthodontics
NCT04398511Phase 2Completed
- Sponsor
- Universidade de Passo Fundo
- Start
- Jan 2019
- Primary completion
- Nov 2019
- Modality
- Yeast Strains, Defined Consortia, Bacterial Strains
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lactobacillus brevis cd2 in traumatic oral lesions (2 arms), sponsored by Universidade de Passo Fundo. Primary endpoints: Number of days without traumatic oral lesions at 21 days and Oral pain scale at 21 days. Started Jan 2019; status: completed.
02
Drugs
lactobacillus brevis cd2
03
Conditions
traumatic oral lesions
Beyond the preview
Go deeper on NCT04398511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398511.